異位性皮膚炎

Topical melatonin has never been tried for treatment of patients with AD. Whether the immunomodulatory and skin-protective effects of topical melatonin could be applied for effective treatment in children with AD is of great interest. Our study aims to evaluate the effectiveness of topical melatonin for the treatment of children with AD.

Melatonin

10%

The primary outcome is the SCORAD index for evaluation of AD disease severity. Secondary outcomes included the objective sleep parameters measured by actigraphy, the patient’s subjective description of the change in sleep and dermatitis severity, quality of life of patients and their family (evaluated by the Children’s Dermatitis Quality of Life Index and the Dermatitis Family Index)

Patients will be recruited from the pediatric and dermatology outpatient departments of National Taiwan University Hospital and Taipei City Hospital Renai Branch.
Inclusion criteria:
The subject must meet all the criteria listed below both at screening and baseline:
(1) Patients with physician-diagnosed AD involving at least 5% of the total body surface area
(2) Age between 2 and 18 years of age
Exclusion criteria:
(1) Those who failed oral or topical immunosuppressant treatment
(2) Those taking oral immunosuppressants
(3) Those with skin infection or skin disease other than AD
(4) Those with autoimmune disease or endocrine disorders
(5) Those who are pregnant or lactating
(6) Those taking sedative medication or antidepressants
(7) Those with documented sleep disorders such as dyssomnias, parasomnias, and circadian rhythm sleep disorders
(8) Those who were unable to fully cooperate
(9) Those who had any other condition or earlier/current treatment which would render the participant ineligible for the study

Patients will be recruited from the pediatric and dermatology outpatient departments of National Taiwan University Hospital and Taipei City Hospital Renai Branch.
Inclusion criteria:
The subject must meet all the criteria listed below both at screening and baseline:
(1) Patients with physician-diagnosed AD involving at least 5% of the total body surface area
(2) Age between 2 and 18 years of age
Exclusion criteria:
(1) Those who failed oral or topical immunosuppressant treatment
(2) Those taking oral immunosuppressants
(3) Those with skin infection or skin disease other than AD
(4) Those with autoimmune disease or endocrine disorders
(5) Those who are pregnant or lactating
(6) Those taking sedative medication or antidepressants
(7) Those with documented sleep disorders such as dyssomnias, parasomnias, and circadian rhythm sleep disorders
(8) Those who were unable to fully cooperate
(9) Those who had any other condition or earlier/current treatment which would render the participant ineligible for the study